ACIU

AC Immune S.A. ACIU

ACIU
AC Immune S.A. ALDX
Aldeyra Therapeutics, Inc. CLLS
Cellectis S.A. ANRO
Alto Neuroscience, Inc. SLN
Silence Therapeutics plc AMRN
Amarin Corporation plc CTNM
Contineum Therapeutics, Inc. Class A Common Stock LYEL
Lyell Immunopharma, Inc. MREO
Mereo BioPharma Group plc ANNX
Annexon, Inc.

Net profit

EBITDA

P/E Ratio

Capitalization

Performance

Periode ACIU ALDX CLLS ANRO SLN AMRN CTNM LYEL MREO ANNX
6M 52.78 % 77.29 % 195.00 % 694.27 % 10.78 % 4.35 % 215.62 % 239.56 % -30.84 % 111.75 %
YTD 6.14 % 7.66 % 128.18 % 311.64 % -12.80 % 32.86 % -20.44 % 152.17 % -41.96 % -9.91 %
1Y 9.21 % 15.16 % 153.37 % 395.33 % -0.95 % 53.70 % -16.22 % 173.36 % -40.03 % 0.10 %
3Y 61.76 % -7.57 % 117.37 % -12.90 % -55.09 % -41.55 % -25.19 % -46.50 % 246.42 % -10.88 %
5Y -44.90 % -25.37 % -84.53 % -12.90 % -67.00 % -86.03 % -25.19 % -90.37 % -44.86 % -82.90 %
10Y -80.68 % -16.74 % -85.13 % -12.90 % -67.85 % -63.39 % -25.19 % -90.37 % -69.46 % -72.10 %
From the beginning -80.68 % -21.94 % -90.05 % -12.90 % -67.85 % -99.88 % -25.19 % -90.37 % -69.46 % -72.10 %

Dividend